€11M Dengue Vaccine Project Launches for Africa

Scientists from four continents are joining forces to tackle a growing threat that climate change is bringing to Africa's doorstep: dengue fever.

The DENSTAR project launched in June 2026 with €11.09 million in funding to fast-track a promising new dengue vaccine for use across sub-Saharan Africa. The four-year initiative brings together researchers from Africa, Europe, Asia, and North America to generate the evidence needed for regulatory approval of DengiAll, a next-generation vaccine designed to protect against all four types of dengue virus.

Dengue fever, transmitted by infected mosquitoes, traditionally plagued parts of Asia and Latin America. But rising temperatures, rapid city growth, and expanding mosquito habitats are now pushing the disease into African communities where healthcare systems aren't yet prepared.

Professor Ellis Owusu-Dabo from Ghana's Kwame Nkrumah University of Science and Technology is leading the scientific work. He warns that infections are becoming increasingly common across the region, ranging from mild illness to potentially fatal cases in the most severe situations.

What makes this vaccine different is its practicality for widespread use. DengiAll requires just one dose instead of multiple shots, and patients don't need blood tests before getting vaccinated. The vaccine is also cost-efficient to produce and designed for easy manufacturing in multiple locations, making it ideal for broad immunization programs in countries with limited resources.

The research team will use controlled human infection studies to test how well the vaccine protects against Dengue Virus Serotype 4, an area where no existing vaccine has proven effective. These findings will strengthen the scientific case for safety and help build public trust in future vaccination campaigns.

The European Union is funding the project through its Global Health program. Italy's Sclavo Vaccines Association is coordinating the consortium, which includes leading universities, vaccine manufacturers, and public health organizations.

The Ripple Effect

Beyond developing the vaccine itself, DENSTAR is investing in Africa's scientific future. The project will train Master's and PhD students while building up local research centers to conduct high-quality clinical trials. This creates lasting infrastructure and expertise that will benefit participating countries long after the vaccine reaches the market.

Dr. Khalid Ali Syed from Panacea Biotec Limited says the impact will extend far beyond dengue prevention. Reducing the disease burden means improved quality of life, less pressure on stretched healthcare systems, and protection of people's right to healthy, productive lives.

Professor Donata Medaglini, who coordinates the project, describes it as a true public-private partnership bringing together the world's top vaccine experts. She's optimistic that DengiAll will eventually receive approval not just in Africa but in other regions where dengue poses a growing threat.

For millions of Africans living with the reality of climate change, this vaccine represents hope that science can adapt as quickly as the threats we face.